Project description
A platform for predicting neurotoxicity of drug candidates
Many drug candidates can introduce toxicity in the central nervous system, which can be poorly predicted during the research and development process. To address this problem, the EU-funded NeuroDeRisk project will study the mechanisms of neurotoxicity, specifically manifested as seizures, psychiatric changes and peripheral neuropathies. Researchers will develop a platform that integrates biological models, artificial intelligence, biomarkers, omics data and compound design tools to improve risk-assessment during the drug development pipeline. This platform will support decision-making in the pharmaceutical industry, offering better protection of human volunteers and patients.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- natural sciencescomputer and information sciencesartificial intelligence
- natural sciencesbiological sciencesneurobiology
Programme(s)
Funding Scheme
IMI2-RIA - Research and Innovation actionCoordinator
Participants (17)
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
2344 Maria Enzersdorf
63000 Clermont Ferrand
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.